Tag Archive for: Immuno-oncology

Updated clinical safety and efficacy data for iOnctura’s roginolisib presented at ESMO Immuno-Oncology Congress 2023

/in

Updated safety and clinical efficacy data presented at leading immuno-oncology conference Exploratory studies suggest roginolisib boosts antitumoral immunity, whilst simultaneously disrupting tumor survival mechanisms Data suggest the potential of radiomics to assess changes in lesions over time, adding value above RECIST (Response Evaluation Criteria in Solid Tumors) Geneva, Switzerland and Amsterdam, The Netherlands, 8 December […]

Read more

Kling Bio Announces Appointment of Dr Stefano Gullà as Chief Scientific Officer

/in

Experienced, innovative biotech and pharma leader with demonstrated success in discovery and development of new therapeutic technologies  Amsterdam, NLD – 5 December 2023 – Kling Bio (“Kling” or “the Company”), a biotech company developing antibody-based drugs against targets identified from its immortalized B-cell platform, is pleased to announce the appointment of Dr Stefano Gullà as […]

Read more

IO Biotech Announces 2023 Third Quarter Results

/in
Read more

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

/in

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology platform, announced the appointment of Helen Collins, MD, to its board of directors. Dr. Collins is an industry veteran with significant experience in oncology/hematology drug development and will […]

Read more

SOTIO Enters Licensing Agreement With Synaffix to Expand ADC Pipeline

/in

Synaffix to provide access to proprietary Antibody-Drug Conjugate (ADC) technologies  SOTIO to develop up to three next generation bioconjugates  Total potential deal value of up to $740 million, plus royalties on commercial sales for three ADC programs  AMSTERDAM, THE NETHERLANDS, 16 September 2023 — Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage […]

Read more
© Optimum Strategic Communications.